D-0042-2024 Class I
FDA drug recall D-0042-2024 was initiated by Scynexis, Inc. on Sep 25, 2023 and is designated Class I. Reason for recall: Cross Contamination with Other Products: Potential cross-contamination of ibrexafungerp citrate drug substance with ezetimibe (a non-antibacterial beta-lactam compound). Affected quantity: 17,376.
Recall details
- Product Type
- Drugs
- Report Date
- Oct 18, 2023
- Initiation Date
- Sep 25, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 17,376
Product description
BREXAFEMME (Ibrexafungerp) tablets 150 mg, 4 count cartons, Rx Only, Manufactured for and distributed by SCYNEXIS, Inc., Jersey City, NJ 07302 NDC 75788-115-04
Reason for recall
Cross Contamination with Other Products: Potential cross-contamination of ibrexafungerp citrate drug substance with ezetimibe (a non-antibacterial beta-lactam compound).
Distribution pattern
Nationwide in the US.
Code information
Lot# LF21000008, Exp. 11/30/2023 Lot# LF22000051, Exp. 11/30/2025
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0042-2024
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026